CoChat
Sign Up
Cited by 176

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

ECM formation and degradation during fibrosis, repair, and regeneration

Mayorca-Guiliani, Alejandro E., Leeming, Diana Julie, Henriksen, Kim, Mortensen, Joachim Høg, Nielsen, Signe Holm, Anstee, Quentin M., Sanyal, Arun J., Karsdal, Morten A., Schuppan, Detlef·2025·npj Metabolic Health and Disease
DOI 10.1038/s44324-025-00063-4PMC PMC12441159
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44324-025-00063-4

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 282

  1. Reuten, R., Mayorca-Guiliani, A. E. & Erler, J. T. Matritecture: mapping the extracellular matrix architecture during health and disease. Matrix Biol. 14, 100102 (2022). · DOI
  2. Mayorca-Guiliani, A. E. et al. ISDoT: In situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix. Nat. Med. 23, 890–898 (2017). · DOI
  3. Mayorca-Guiliani, A. E. et al. Decellularization and antibody staining of mouse tissues to map native extracellular matrix structures in 3D. Nat. Protoc. 14, 3395–3425 (2019). · DOI · Paper page
  4. Li, J. et al. Spatially resolved proteomic map shows that extracellular matrix regulates epidermal growth. Nat. Commun. 13, 4012 (2022). · DOI
  5. Tsutsui, K. et al. Mapping the molecular and structural specialization of the skin basement membrane for inter-tissue interactions. Nat. Commun. 12, 2577 (2021). · DOI
  6. Pozzi, A., Yurchenco, P. D. & Iozzo, R. V. The nature and biology of basement membranes. Matrix Biol. 57–58, 1–11 (2017). · DOI
  7. Reuten, R. et al. Basement membrane stiffness determines metastases formation. Nat. Mater. 20, 892–903 (2021). · DOI
  8. He, Y., Sardar, S., Bay-Jensen, A. C., Port, H. & Karsdal, M. A. Type IX collagen. In Biochemistry of Collagens, Laminins and Elastin 89–95. https://doi.org/10.1016/B978-0-443-15617-5.00034-2 (Elsevier, 2024). · DOI
  9. Chen, M. et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. Genet. 32, 670–675 (2002). · DOI
  10. Patten, J. & Wang, K. Fibronectin in development and wound healing. Adv. Drug Deliv. Rev. 170, 353–368 (2021). · DOI
  11. Dalton, C. J. & Lemmon, C. A. Fibronectin: molecular structure, fibrillar structure and mechanochemical signaling. Cells 10, 2443 (2021). · DOI
  12. Moretti, L., Stalfort, J., Barker, T. H. & Abebayehu, D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J. Biol. Chem. 298, 101530 (2022). · DOI · Paper page
  13. Barker, H. E., Cox, T. R. & Erler, J. T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 12, 540–552 (2012). · DOI
  14. Lyu, C. et al. Advanced glycation end-products as mediators of the aberrant crosslinking of extracellular matrix in scarred liver tissue. Nat. Biomed. Eng. 7, 1437–1454 (2023). · DOI · Paper page
  15. Maller, O. et al. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat. Mater. 20, 548–559 (2021). · DOI
  16. Schuppan, D., Ruehl, M., Somasundaram, R. & Hahn, E. G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 21, 351–372 (2001). · DOI
  17. Somasundaram, R. & Schuppan, D. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J. Biol. Chem. 271, 26884–26891 (1996). · DOI
  18. Schuppan, D. et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 114, 139–152 (1998). · DOI
  19. Ruehl, M. et al. The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline. J. Biol. Chem. 277, 26872–26878 (2002). · DOI
  20. Somasundaram, R. et al. Collagens serve as an extracellular store of bioactive interleukin 2. J. Biol. Chem. 275, 38170–38175 (2000). · DOI
  21. Somasundaram, R. et al. Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J. Biol. Chem. 277, 3242–3246 (2002). · DOI
  22. Rafaeva, M. et al. Modeling metastatic colonization in a decellularized organ scaffold-based perfusion bioreactor. Adv. Health. Mater. 11, e2100684 (2022). · DOI
  23. Karsdal, M. A. et al. The good and the bad collagens of fibrosis—their role in signaling and organ function. Adv. Drug Deliv. Rev. 121, 43–56 (2017). · DOI · Paper page
  24. Maquart, F. X. & Monboisse, J. C. Extracellular matrix and wound healing. Pathol. Biol. 62, 91–95 (2014). · DOI
  25. Karsdal, M. A. et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G807–G830 (2015). · DOI
  26. O’Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997). · DOI · Paper page
  27. Yamaguchi, Y. et al. A peptide derived from endostatin ameliorates organ fibrosis. Sci. Transl. Med 4, 136ra71 (2012). · DOI
  28. Hamano, Y. & Kalluri, R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys. Res Commun. 333, 292–298 (2005). · DOI
  29. Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217–238 (2021). · DOI
  30. Brown, G. T. & Kleiner, D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65, 1080–1086 (2016). · DOI
  31. Bissell, M. J. & Hines, W. C. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med 17, 320–329 (2011). · DOI
  32. Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science (1979) 326, 1216–1219 (2009).
  33. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem. Cell Lineage Specif. Cell 126, 677–689 (2006).
  34. Massagué, J. & Sheppard, D. TGF-β signaling in health and disease. Cell 186, 4007–4037 (2023). · DOI · Paper page
  35. Huang, J. et al. Fibulin-4 deficiency results in ascending aortic aneurysms. Circ. Res 106, 583–592 (2010). · DOI
  36. McLaughlin, P. J. et al. Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice. Hum. Mol. Genet 16, 3059–3070 (2007). · DOI
  37. Massam-Wu, T. et al. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGFβ. J. Cell Sci. 123, 3006–3018 (2010). · DOI
  38. Klingberg, F. et al. The ED-A domain enhances the capacity of fibronectin to store latent TGF-β binding protein-1 in the fibroblast matrix. J. Cell Sci. https://doi.org/10.1242/jcs.201293 (2018). · DOI
  39. Horiguchi, M., Ota, M. & Rifkin, D. B. Matrix control of transforming growth factor- function. J. Biochem. 152, 321–329 (2012). · DOI
  40. Schaefer, L. et al. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J. 15, 559–561 (2001). · DOI
  41. Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687–690 (2010). · DOI
  42. Birch, H. L. Extracellular matrix and ageing. 169–190. https://doi.org/10.1007/978-981-13-2835-0_7 (2018). · DOI
  43. Jiang, D. et al. Injury triggers fascia fibroblast collective cell migration to drive scar formation through N-cadherin. Nat. Commun. 11, 5653 (2020). · DOI
  44. Correa-Gallegos, D. et al. Patch repair of deep wounds by mobilized fascia. Nature 576, 287–292 (2019). · DOI · Paper page
  45. Baer, J. M. et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Nat. Immunol. 24, 1443–1457 (2023). · DOI
  46. Dey, S. et al. Loss of miR-29a/b1 promotes inflammation and fibrosis in acute pancreatitis. JCI Insight 6, (2021). · DOI
  47. Panizo, S. et al. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int. J. Mol. Sci. 22, 408 (2021). · DOI
  48. Tanwar, S., Rhodes, F., Srivastava, A., Trembling, P. M. & Rosenberg, W. M. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J. Gastroenterol. 26, 109–133 (2020). · DOI
  49. Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P. & Liu, F.-F. Targeting metabolic dysregulation for fibrosis therapy. Nat. Rev. Drug Discov. 19, 57–75 (2020). · DOI
  50. Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040 (2012). · DOI · Paper page
  51. Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555–566 (2020). · DOI · Paper page
  52. Simon, A. & Tanaka, E. M. Limb regeneration. WIREs Dev. Biol. 2, 291–300 (2013). · DOI
  53. Godwin, J., Kuraitis, D. & Rosenthal, N. Extracellular matrix considerations for scar-free repair and regeneration: insights from regenerative diversity among vertebrates. Int J. Biochem Cell Biol. 56, 47–55 (2014). · DOI
  54. Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13, 643–654.e9 (2015). · DOI · Paper page
  55. Siddiqui, M. S. et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 156–163.e2 (2019). · DOI
  56. Sanyal, A. J. et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat. Med 29, 2656–2664 (2023). · DOI
  57. Bihlet, A. R. et al. Clinical drug development using dynamic biomarkers to enable personalized health care in COPD. Chest 148, 16–23 (2015). · DOI
  58. Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714–725 (2023). · DOI · Paper page
  59. Rasmussen, D. G. K. et al. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial. Cardiovasc. Diabetol. 21, 261 (2022). · DOI
  60. Borisov, A. N., Kutz, A., Christ, E. R., Heim, M. H. & Ebrahimi, F. Canagliflozin and metabolic associated fatty liver disease in patients with diabetes mellitus: new insights from CANVAS. J. Clin. Endocrinol. Metab. 108, 2940–2949 (2023). · DOI
  61. Harrison, S. A. et al. Effects of resmetirom on noninvasive endpoints in a 36‐week phase 2 active treatment extension study in patients with NASH. Hepatol. Commun. 5, 573–588 (2021). · DOI · Paper page
  62. Mehal, W. Z., Iredale, J. & Friedman, S. L. Scraping fibrosis: expressway to the core of fibrosis. Nat. Med. 17, 552–553 (2011). · DOI
  63. Roh, H. C. et al. Adipocytes fail to maintain cellular identity during obesity due to reduced PPARγ activity and elevated TGFβ-SMAD signaling. Mol. Metab. 42, 101086 (2020). · DOI · Paper page
  64. Zhao, Z. et al. TGF-β promotes pericyte-myofibroblast transition in subretinal fibrosis through the Smad2/3 and Akt/mTOR pathways. Exp. Mol. Med. 54, 673–684 (2022). · DOI
  65. Zou, F., Li, Y., Zhang, S. & Zhang, J. DP1 (Prostaglandin D 2 Receptor 1) activation protects against vascular remodeling and vascular smooth muscle cell transition to myofibroblasts in angiotensin II–induced hypertension in mice. Hypertension 79, 1203–1215 (2022). · DOI
  66. Little, K. et al. Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration. J. Neuroinflammation 17, 355 (2020). · DOI
  67. Xu, R. et al. Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway. Mol. Med. 29, 59 (2023). · DOI
  68. Lovisa, S. et al. Endothelial-to-mesenchymal transition compromises vascular integrity to induce Myc-mediated metabolic reprogramming in kidney fibrosis. Sci. Signal 13, 998–1009 (2020). · DOI
  69. Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998–1009 (2015). · DOI
  70. Younesi, F. S., Miller, A. E., Barker, T. H., Rossi, F. M. V. & Hinz, B. Fibroblast and myofibroblast activation in normal tissue repair and fibrosis. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-024-00716-0 (2024). · DOI
  71. Ezzo, M. & Hinz, B. Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases. Pharm. Ther. 250, 108528 (2023). · DOI
  72. Hinz, B. The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship. Matrix Biol. 47, 54–65 (2015). · DOI
  73. Sobierajska, K., Wawro, M. E. & Niewiarowska, J. Oxidative stress enhances the TGF-β2-RhoA-MRTF-A/B axis in cells entering endothelial-mesenchymal transition. Int. J. Mol. Sci. 23, 2062 (2022). · DOI
  74. Alharthi, A., Verma, A., Sabbineni, H., Adil, M. S. & Somanath, P. R. Distinct effects of pharmacological inhibition of stromelysin1 on endothelial‐to‐mesenchymal transition and myofibroblast differentiation. J. Cell Physiol. 236, 5147–5161 (2021). · DOI
  75. Shiju, T. M., Sampaio, L. P., Martinez, V. V., Hilgert, G. S. L. & Wilson, S. E. Transforming growth factor beta-3 localization in the corneal response to epithelial-stromal injury and effects on corneal fibroblast transition to myofibroblasts. Exp. Eye Res. 235, 109631 (2023). · DOI
  76. Kolosova, I., Nethery, D. & Kern, J. A. Role of Smad2/3 and p38 MAP kinase in TGF‐β1‐induced epithelial–mesenchymal transition of pulmonary epithelial cells. J. Cell Physiol. 226, 1248–1254 (2011). · DOI
  77. Zhou, X. et al. Amelioration of fibrotic remodeling of human 3‐dimensional full‐thickness skin by transglutamase 2 inhibition. Arthritis Rheumatol. 75, 1619–1627 (2023). · DOI
  78. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009). · DOI · Paper page
  79. Nguyen, X.-X. et al. Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 320, L29–L40 (2021). · DOI
  80. Coelho, N. M. et al. Discoidin domain receptor 1 mediates myosin-dependent collagen contraction. Cell Rep. 18, 1774–1790 (2017). · DOI
  81. Zhan, L. & Li, J. The role of TRPV4 in fibrosis. Gene 642, 1–8 (2018). · DOI
  82. Parichatikanond, W., Duangrat, R. & Mangmool, S. Gαq protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-β1/ERK axis in human cardiac fibroblasts. Eur. J. Pharm. 951, 175780 (2023). · DOI
  83. Razinia, Z. et al. Stiffness-dependent motility and proliferation uncoupled by deletion of CD44. Sci. Rep. 7, 16499 (2017). · DOI
  84. Cain, S. A., Woods, S., Singh, M., Kimber, S. J. & Baldock, C. ADAMTS6 cleaves the large latent TGFβ complex and increases the mechanotension of cells to activate TGFβ. Matrix Biol. 114, 18–34 (2022). · DOI
  85. Rose, K. W. J., Taye, N., Karoulias, S. Z. & Hubmacher, D. Regulation of ADAMTS proteases. Front. Mol.Biosci. 8, (2021). · DOI
  86. Noda, K. et al. Latent TGF-β binding protein 4 promotes elastic fiber assembly by interacting with fibulin-5. Proc. Natl. Acad. Sci. USA 110, 2852–2857 (2013). · DOI
  87. Camarena, V. et al. ADAMTSL2 mutations determine the phenotypic severity in geleophysic dysplasia. JCI Insight 110, 2852-2857 (2024). · DOI
  88. Corey, K. E. et al. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J. Hepatol. 76, 25–33 (2022). · DOI · Paper page
  89. Dagoneau, N. et al. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am. J. Hum. Genet. 75, 801–806 (2004). · DOI
  90. Aoki, F. & Kojima, I. Therapeutic potential of follistatin to promote tissue regeneration and prevent tissue fibrosis. Endocr. J. 54, 849–854 (2007). · DOI
  91. Innis, C. A. & Hyvönen, M. Crystal structures of the heparan sulfate-binding domain of follistatin. Insights into ligand binding. J. Biol. Chem. 278, 39969–39977 (2003). · DOI
  92. Kiagiadaki, F. et al. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 891–899 (2018). · DOI
  93. Patella, S., Phillips, D. J., Tchongue, J., de Kretser, D. M. & Sievert, W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am. J. Physiol.-Gastrointest. Liver Physiol. 290, G137–G144 (2006). · DOI
  94. Nordholm, A. et al. Activin A inhibition reduces kidney fibrosis and normalizes bone abnormalities in AKI. J. Am. Soc. Nephrol. 35 (2024). · DOI
  95. Maeshima, A. et al. Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction. Biomed. Res. Int. 2014, 376191 (2014). · DOI
  96. Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192–201 (2015). · DOI
  97. Di Rocco, M. et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat. Med 29, 2615–2624 (2023). · DOI
  98. Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478–1490 (2023). · DOI
  99. Nusse, R. & Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99–109 (1982). · DOI
  100. Somanader, D. V. N., Zhao, P., Widdop, R. E. & Samuel, C. S. The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin. Biochem Pharm. 223, 116130 (2024). · DOI
  101. Froidure, A. et al. Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis. Eur. Respir. Rev. 29, 190140 (2020). · DOI
  102. Skronska-Wasek, W., Gosens, R., Königshoff, M. & Baarsma, H. A. WNT receptor signalling in lung physiology and pathology. Pharm. Ther. 187, 150–166 (2018). · DOI
  103. Kneidinger, N. et al. Activation of the WNT/β-catenin pathway attenuates experimental emphysema. Am. J. Respir. Crit. Care Med. 183, 723–733 (2011). · DOI
  104. Blyszczuk, P. et al. Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. Eur. Heart J. ehw116, https://doi.org/10.1093/eurheartj/ehw116 (2016). · DOI
  105. Li, S.-S. et al. Targeting the Wnt/β-catenin signaling pathway as a potential therapeutic strategy in renal tubulointerstitial fibrosis. Front. Pharmacol. 12 (2021). · DOI
  106. Gehrke, A. R. et al. Acoel genome reveals the regulatory landscape of whole-body regeneration. Science 363, eaau6173 (2019). · DOI
  107. Mitoh, S. & Yusa, Y. Extreme autotomy and whole-body regeneration in photosynthetic sea slugs. Curr. Biol. 31, R233–R234 (2021). · DOI
  108. Wei, X. et al. Single-cell Stereo-seq reveals induced progenitor cells involved in axolotl brain regeneration. Science 377, eabp9444 (2022). · DOI · Paper page
  109. Poss, K. D., Wilson, L. G. & Keating, M. T. Heart regeneration in zebrafish. Science (1979) 298, 2188–2190 (2002).
  110. Stewart, S., Tsun, Z.-Y. & Belmonte, J. C. I. A histone demethylase is necessary for regeneration in zebrafish. Proc. Natl. Acad. Sci. USA 106, 19889–19894 (2009). · DOI
  111. Brown, A. C. et al. Fibrin network changes in neonates after cardiopulmonary bypass. Anesthesiology 124, 1021–1031 (2016). · DOI
  112. Leung, A., Crombleholme, T. M. & Keswani, S. G. Fetal wound healing. Curr. Opin. Pediatr. 24, 371–378 (2012). · DOI
  113. Xu, L. et al. Transforming growth factor β3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-γ/IL-4 balance. Immunol. Lett. 162, 27–33 (2014). · DOI
  114. Singh, K., Sachan, N., Ene, T., Dabovic, B. & Rifkin, D. Latent transforming growth factor β binding protein 3 controls adipogenesis. Matrix Biol. 112, 155–170 (2022). · DOI
  115. Klingberg, F. et al. Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation. J. Cell Biol. 207, 283–297 (2014). · DOI
  116. Xia, H. et al. Tissue repair and regeneration with endogenous stem cells. Nat. Rev. Mater. 3, 174–193 (2018). · DOI
  117. Mascharak, S. et al. Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring. Science 372, eaba2374 (2021). · DOI
  118. Monaghan-Benson, E., Aureille, J. & Guilluy, C. ECM stiffness regulates lung fibroblast survival through RasGRF1-dependent signaling. J. Biol. Chem. 301, 108161 (2025). · DOI
  119. Jiang, C. et al. Collagen signaling and matrix stiffness regulate multipotency in glandular epithelial stem cells in mice. Nat. Commun. 15, 10482 (2024). · DOI
  120. Paranjpe, S. et al. Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation. Hepatology 64, 1711–1724 (2016). · DOI · Paper page
  121. French, B. A. & Holmes, J. W. Implications of scar structure and mechanics for post-infarction cardiac repair and regeneration. Exp. Cell Res. 376, 98–103 (2019). · DOI
  122. Rudolph, K. L. et al. Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology 30, 1159–1166 (1999). · DOI
  123. Drixler, T. A. et al. Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy. Br. J. Surg. 90, 1384–1390 (2003). · DOI
  124. Zhou, B. et al. Matrix metalloproteinases-9 deficiency impairs liver regeneration through epidermal growth factor receptor signaling in partial hepatectomy mice. J. Surg. Res. 197, 201–209 (2015). · DOI
  125. Sparrelid, E. et al. Serial assessment of growth factors associated with liver regeneration in patients operated with associating liver partition and portal vein ligation for staged hepatectomy. Eur. Surg. Res. 59, 72–82 (2018). · DOI
  126. Nejak-Bowen, K., Orr, A., Bowen, W. C. & Michalopoulos, G. K. Conditional genetic elimination of hepatocyte growth factor in mice compromises liver regeneration after partial hepatectomy. PLoS ONE 8, e59836 (2013). · DOI
  127. Volk, A., Michalopoulos, G., Weidner, M. & Gebhardt, R. Different proliferative responses of periportal and pericentral rat hepatocytes to hepatocyte growth factor. Biochem. Biophys. Res. Commun. 207, 578–584 (1995). · DOI
  128. Gallai, M. et al. Proteoglycan gene expression in rat liver after partial hepatectomy. Biochem. Biophys. Res. Commun. 228, 690–694 (1996). · DOI
  129. Klein, S. et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130, 1564–1572 (2006). · DOI
  130. Lefere, S. et al. Bariatric surgery and the liver—mechanisms, benefits, and risks. Obes. Rev. 22, e13294 (2021). · DOI
  131. Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013). · DOI · Paper page
  132. Rockey, D. C. & Friedman, S. L. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. Gastroenterology 160, 1502–1520.e1 (2021). · DOI
  133. Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020). · DOI · Paper page
  134. Nielsen, M. J. et al. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 35, 429–437 (2015). · DOI
  135. Harrison, S. A. et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol. Commun. 5, 573–588 (2021). · DOI · Paper page
  136. Garbern, J. C. & Lee, R. T. Heart regeneration: 20 years of progress and renewed optimism. Dev. Cell 57, 424–439 (2022). · DOI
  137. Vujic, A., Natarajan, N. & Lee, R. T. Molecular mechanisms of heart regeneration. Semin. Cell Dev. Biol. 100, 20–28 (2020). · DOI
  138. Gourdie, R. G., Dimmeler, S. & Kohl, P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat. Rev. Drug Discov. 15, 620–638 (2016). · DOI
  139. van den Borne, S. W. M. et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 7, 30–37 (2010). · DOI
  140. Roche, P. L., Filomeno, K. L., Bagchi, R. A. & Czubryt, M. P. Intracellular signaling of cardiac fibroblasts. in Comprehensive Physiology 721–760. https://doi.org/10.1002/cphy.c140044 (Wiley, 2015). · DOI
  141. Grotendorst, G. R. & Duncan, M. R. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 19, 729–738 (2005). · DOI
  142. Maisel, A. S. & Choudhary, R. Biomarkers in acute heart failure—state of the art. Nat. Rev. Cardiol. 9, 478–490 (2012). · DOI
  143. Ahmad, T., Fiuzat, M., Felker, G. M. & O’Connor, C. Novel biomarkers in chronic heart failure. Nat. Rev. Cardiol. 9, 347–359 (2012). · DOI
  144. Chirinos, J. A. et al. Endotrophin, a collagen VI formation-derived peptide, in heart failure. NEJM Evid. 1, EVIDoa2200091 (2022). · DOI
  145. Chambers, R. C. & Mercer, P. F. Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann. Am. Thorac. Soc. 12, S16–S20 (2015). · DOI
  146. Xu, J. et al. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 64 A, 731–739 (2009). · DOI
  147. Kathiriya, J. J. et al. Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5+ basal cells. Nat. Cell Biol. 24, 10–23 (2022). · DOI
  148. Melo-Narváez, M. C., Stegmayr, J., Wagner, D. E. & Lehmann, M. Lung regeneration: implications of the diseased niche and ageing. Eur. Respir. Rev. 29, 200222 (2020). · DOI
  149. Wu, H. et al. Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem. Cells Cell 180, 107–121.e17 (2020). · DOI
  150. Knüppel, L. et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. inhibition of collagen fibril assembly. Am. J. Respir. Cell Mol. Biol. 57, 77–90 (2017). · DOI
  151. Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A. & Kamil, H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm. Med. 21, 411 (2021). · DOI
  152. Wind, S. et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin. Pharmacokinet. 58, 1131–1147 (2019). · DOI
  153. Bhatt, S. P. et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N. Engl. J. Med. 389, 205–214 (2023). · DOI
  154. Bhatt, S. P. et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N. Engl. J. Med. 390, 2274–2283 (2024). · DOI
  155. Balzer, M. S. et al. Single-cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration. Nat. Commun. 13, 4018 (2022). · DOI
  156. Doke, T. et al. Single-cell analysis identifies the interaction of altered renal tubules with basophils orchestrating kidney fibrosis. Nat. Immunol. 23, 947–959 (2022). · DOI
  157. Fioretto, P., Steffes, M. W., Sutherland, D. E. R., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69–75 (1998). · DOI
  158. Tajima, K. et al. An organ-derived extracellular matrix triggers in situ kidney regeneration in a preclinical model. NPJ Regen. Med. 7, 18 (2022). · DOI
  159. Greenberg, J. H. et al. Urine biomarkers of kidney tubule health, injury, and inflammation are associated with progression of CKD in children. J. Am. Soc. Nephrol. 32, 2664–2677 (2021). · DOI
  160. Sparding, N. et al. Unique biomarkers of collagen type III remodeling reflect different information regarding pathological kidney tissue alterations in patients with IgA nephropathy. Biomolecules 13, 1093 (2023). · DOI
  161. Zhang, X.-Q. et al. Serum lysyl oxidase is a potential diagnostic biomarker for kidney fibrosis. Am. J. Nephrol. 51, 907–918 (2020). · DOI
  162. Zewinger, S. et al. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J. Am. Soc. Nephrol. 29, 2722–2733 (2018). · DOI
  163. Genovese, F. et al. Collagen type III and VI remodeling biomarkers are associated with kidney fibrosis in lupus nephritis. Kidney360 2, 1473–1481 (2021). · DOI
  164. Sparding, N. et al. Circulating levels of endotrophin are prognostic for long-term mortality after AKI. Kidney360 3, 809–817 (2022). · DOI
  165. D’Alessio, S. et al. Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat. Rev. Gastroenterol. Hepatol. 19, 169–184 (2022). · DOI
  166. Domislović, V. et al. Differences in extra cellular matrix remodelling in highly active Crohn’s disease and ulcerative colitis. J. Crohns Colitis 14, S156–S157 (2020). · DOI
  167. Mortensen, J. H. et al. The intestinal tissue homeostasis–the role of extracellular matrix remodeling in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 13, 977–993 (2019). · DOI
  168. van Haaften, W. T. et al. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease. Aliment Pharm. Ther. 46, 26–39 (2017). · DOI
  169. Mortensen, J. H. et al. Fragments of citrullinated and MMP-degraded vimentin and MMP-degraded type III collagen are novel serological biomarkers to differentiate Crohn’s disease from ulcerative colitis. J. Crohns Colitis 9, 863–872 (2015). · DOI
  170. Bourgonje, A. R. et al. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease. Aliment. Pharmacol. Ther. 1–19. https://doi.org/10.1111/apt.17063 (2022). · DOI
  171. Alexdottir, M. S. et al. Serological biomarkers of extracellular matrix turnover and neutrophil activity are associated with long-term use of vedolizumab in patients with Crohn’s disease. Int J. Mol. Sci. 23, i468–i469 (2022). · DOI
  172. van Haaften, W. T. et al. Serological biomarkers of tissue turnover identify responders to anti-TNF therapy in Crohn’s disease: a pilot study. Clin. Transl. Gastroenterol. 11, e00217 (2020). · DOI
  173. Mortensen, J. H. et al. The citrullinated and MMP-degraded vimentin biomarker (VICM) predicts early response to anti-TNFα treatment in Crohn’s disease. J. Clin. Gastroenterol. 55, 59–66 (2021). · DOI
  174. Alexdottir, M. S. et al. Serological biomarkers of intestinal collagen turnover identify early response to infliximab therapy in patients with Crohn’ s disease. Int. J. Mol. Sci. 23, 8137 (2022). · DOI
  175. Manon-Jensen, T. et al. Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn’s disease. United Eur. Gastroenterol. J. https://doi.org/10.1177/2050640620977371 (2020). · DOI
  176. Jensen, C. et al. Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders. Cancer Med. 1–8. https://doi.org/10.1002/cam4.1692 (2018). · DOI
  177. Sun, S. et al. Serological assessment of the quality of wound healing processes in Crohn’s disease. J. Gastrointest. Liver Dis. 28, 175–182 (2019). · DOI
  178. Pehrsson, M., Alexdóttir, M. S., Karsdal, M. A., Thakker, P. & Mortensen, J. H. Novel fibro-inflammatory biomarkers associated with disease activity in patients with Crohn’s disease. Expert Rev. Gastroenterol. Hepatol. 00, 1–13 (2023).
  179. Yoo, J. H., Holubar, S. & Rieder, F. Fibrostenotic strictures in Crohn’s disease. Intest Res 18, 379–401 (2020). · DOI
  180. De Bruyn, J. R. et al. Development of fibrosis in acute and longstanding ulcerative colitis. J. Crohns Colitis 9, 966–972 (2015). · DOI
  181. Gordon, I. O. et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment. Pharm. Ther. 47, 922–939 (2018). · DOI
  182. De Bruyn, J. R. et al. Intestinal fibrosis is associated with lack of response to infliximab therapy in Crohn’s disease. PLoS ONE 13, 1–13 (2018). · DOI
  183. Lawrance, I. C. et al. Cellular and molecular mediators of intestinal fibrosis. J. Crohns Colitis j.crohns.2014.09.008, https://doi.org/10.1016/j.crohns.2014.09.008 (2015). · DOI
  184. Neurath, M. F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970–979 (2019). · DOI
  185. Stolfi, C., Troncone, E., Marafini, I. & Monteleone, G. Role of TGF-beta and Smad7 in gut inflammation, fibrosis and cancer. Biomolecules 11, 17 (2020). · DOI
  186. Gundersen, M. D. et al. Fibrosis mediators in the colonic mucosa of acute and healed ulcerative colitis. Clin. Transl. Gastroenterol. 10, e00082 (2019). · DOI
  187. Rieder, F., Brenmoehl, J., Leeb, S., Scholmerich, J. & Rogler, G. Wound healing and fibrosis in intestinal disease. Gut 56, 130–139 (2007). · DOI
  188. Hamilton, A. L. et al. Serologic antibodies in relation to outcome in postoperative Crohn’s disease. J. Gastroenterol. Hepatol. 32, 1195–1203 (2017). · DOI
  189. Zhao, Z., Cheng, W., Qu, W., Shao, G. & Liu, S. Antibiotic alleviates radiation-induced intestinal injury by remodeling microbiota, reducing inflammation, and inhibiting fibrosis. ACS Omega 5, 2967–2977 (2020). · DOI
  190. Ellermann, M. et al. Yersiniabactin-producing adherent/invasive escherichia coli promotes inflammation-associated fibrosis in gnotobiotic Il10−/− Mice. Infect. Immun. 87, e00587-19 (2019). · DOI
  191. Mortensen, J. H. et al. A specific calprotectin neo-epitope [CPa9-HNE] in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity. J. Crohns Colitis 1–14. https://doi.org/10.1093/ecco-jcc/jjac047 (2022). · DOI
  192. Chrysanthopoulou, A. et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J. Pathol. 233, 294–307 (2014). · DOI
  193. Chokr, D. et al. Adherent invasive Escherichia coli (AIEC) strain LF82, but not Candida albicans, plays a profibrogenic role in the intestine. Gut Pathog. 13, 5 (2021). · DOI
  194. O’Donnell, S., O’Sullivan, M., O’Morain, C. A. & Ryan, B. M. The clinical significance of antimicrobial serologic responses within an Irish Crohn’s disease population. Eur. J. Gastroenterol. Hepatol. 25, 1464–1469 (2013). · DOI
  195. Dubinsky, M. C. et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am. J. Gastroenterol. 101, 360–367 (2006). · DOI
  196. Park, J.-S. et al. Lactobacillus acidophilus improves intestinal inflammation in an acute colitis mouse model by regulation of Th17 and treg cell balance and fibrosis development. J. Med Food 21, 215–224 (2018). · DOI
  197. Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 (2006). · DOI · Paper page
  198. Zheng, J. et al. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat. Med 30, 3555–3567 (2024). · DOI
  199. Sandborn, W. J. et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology 158, 2123–2138.e8 (2020). · DOI · Paper page
  200. Roblin, X. et al. Effects of JAK1-preferential inhibitor filgotinib on circulating biomarkers and whole blood genes/pathways of patients with moderately to severely active Crohn’s disease. Inflamm. Bowel Dis. 28, 1207–1218 (2022). · DOI

200 of 282 shown

Cited by

Sorted by citations

See all 176

Metadata

Authors
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D.
Venue
npj Metabolic Health and Disease
Publisher
Springer Science and Business Media LLC
Published
2025-06-10
Volume
3
Issue
1
ISSN
2948-2828
DOI
10.1038/s44324-025-00063-4
PMC
PMC12441159
Cited by
176
References
37
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review